Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Birch pollen allergy vaccine - Anergis

Drug Profile

Birch pollen allergy vaccine - Anergis

Alternative Names: AllerT; AllerT-Birch

Latest Information Update: 19 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Lausanne
  • Developer Anergis
  • Class Antiallergics; Peptide vaccines; Peptides; Tree pollen allergy immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Allergic rhinoconjunctivitis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 31 Dec 2017 Discontinued - Phase-II for Allergic rhinoconjunctivitis in Slovakia, Norway, Germany, Finland, Canada, France, Sweden, Poland, Denmark, Latvia, Lithuania, Switzerland (SC)
  • 26 Sep 2017 Anergis completes a phase II trial in Allergic rhinoconjunctivitis in Denmark, Finland, Germany, Lithuania, Norway, Poland, Slovakia and Sweden (NCT02943720)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top